Importance: Findings from unbiased genetic studies have consistently implicated synaptic protein networks in Schizophrenia (Sz), but the molecular pathology at these networks and their potential contribution to the synaptic and circuit deficits thought to underlie disease symptoms remain unknown.
Synaptic Proteome Alterations in the Primary Auditory Cortex of Schizophrenia

Introduction
Subjects with schizophrenia (Sz) display impairments in the processing of auditory sensory information (1) (2) (3) (4) including auditory event-related potentials (e.g. mismatch negativity) (1, 2, 5, 6) which are generated in layer 3 of primary auditory cortex (A1) (7) (8) (9) . Many individuals with Sz also have deficits in auditory learning (10) , limiting their functional recovery during targeted sensory and cognitive training (11) . In A1, as in other cortical regions, learning requires the formation and stabilization of new dendritic spines (12) (13) (14) and decreased density of layer 3 dendritic spines has been reproducibly observed in multiple brain regions in Sz, including A1 (15) (16) (17) (18) (19) (20) .
Unbiased genetic studies of Sz have implicated synaptic protein networks in disease etiology (21) . This convergence of genetic risk factors is believed to underlie the dendritic spine deficits and information processing alterations observed in the A1 and other cortical regions. Numerous studies have documented the essential role of local synaptic protein trafficking, translation, and degradation in spine formation and plasticity (22) . This local protein homeostasis (proteostasis) is believed to be required for the rapid synaptogenesis and plasticity essential to cortical information processing and new learning (23, 24) . Indeed, blocking synaptic proteostatic processes impairs new synapse formation and learning (25, 26) . Thus, we hypothesized that protein levels at the synapse are altered in the A1 of Sz and that these synaptic alterations are distinct from protein alterations in total grey matter.
To investigate protein levels at the synapse, we utilized a high precision targeted mass spectrometry (MS) approach with a [ (27) to quantify >350 selected proteins in A1 synaptosome enrichments (to measure protein levels within synapses) from 48 pairs of Sz and unaffected comparison subjects, matched for age, sex, and PMI. While targeted-MS is limited in the number of proteins assayable, it has exceptional precision, accuracy, and throughput. To determine if the predicted alterations are synaptosome-specific, identical studies were conducted in total A1 homogenate preparations to measure tissue-wide protein levels. Technical controls were utilized to monitor reproducibility of synaptosome enrichment, sample preparation, and instrument performance. The effects of antipsychotic drug (APD) treatment and postmortem interval (PMI) were assessed in monkey and mouse models, respectively.
We observed robust and highly co-regulated differences in the synaptic levels of canonical mitochondrial and postsynaptic proteins between subject groups, including both glutamate and GABA receptors. Tissue-wide levels of a majority of these proteins did not differ significantly in Sz. These findings indicate a broad and highly coordinated rearrangement of the synaptic proteome likely contributing to synapse and circuit pathology. That these synaptic proteome alterations were largely unexplained by tissue-wide protein level differences suggests they are driven by impairments in synaptic, not cell-wide, proteostasis. Figure 1 provides an overview the experimental design.
Materials & Methods
Human Subjects and Tissue Collection: Brain specimens were obtained from the Allegheny County Office of the Medical Examiner ( Table 1 ) and grey matter was harvested from the auditory cortex as previously described (28, 29) . See Supplement and Figure 1 for details.
Antipsychotic Drug Treated Monkey Tissue:
The tissue utilized here was obtained from previously completed experiments that have been extensively described elsewhere (30) . See Supplement for details.
Mouse PMI Brain Tissue: C57BL/6 Adult Mice, n= 2 per timepoint (0, 6, 12, 18, 24, and 30 hrs), were sacrificed by CO2 asphyxiation followed by cervical dislocation. The carcasses were incubated at room temperature for 2/3 the PMI duration and then placed at 4°C for the final 1/3. The brain was then removed from the skull, the cerebellum discarded, and the hemispheres separated (giving n = 4 hemispheres/time point), flash frozen in isopentane on dry ice, and stored at -80°C.
Sample Preparation: Total grey matter homogenate and synaptosome preparations were obtained using a variation on our sucrose density gradient centrifugation method, validated for use in human postmortem brain tissue (27, 31) . The homogenate preparation is composed of all material present in the A1 grey matter, an aliquot of which is set aside prior to synaptosome enrichment. See Supplement for detailed protocol. To monitor variability in synaptosome preparation in the human cohorts, two 50 mg aliquots of pulverized superior temporal gyrus grey matter from a low PMI human control were included in every third run and assayed alongside subject samples (Figure 1) . To monitory variability in sample preparation after synaptosome enrichment, a pooled control was prepared and assayed alongside subject samples (Figure 1 were generated using data from discovery MS analyses of human grey matter homogenates as well as synaptosome and postsynaptic density enrichments and validated as previously described (27) .
Mass Spectrometry: MS analyses were conducted on a TSQ Quantiva triple stage quadrupole mass spectrometer (ThermoFisher Scientific, Location) with an Ultimate 3000 HPLC (Dionex). 2 µl (~1 μg protein) was loaded on to a 3 µm 120A; 105mm REPROSIL-Pur C18 Picochip (New Objective) at 1 μl/min for 12 min and eluted at 400nl/min over a 25 min gradient from 3-35% mobile phase B (Acetonitrile, 0.1% formic acid).
Selected reaction monitoring transitions were scheduled with 45 second windows. Transitions were monitored, allowing for a cycle time of 1.1 sec, resulting in a dynamic dwell time never falling below 10 msec. The MS instrument parameters were as follows: capillary temperature 275°C, spray voltage 1350 V, and a collision gas of 1.4 mTorr (argon). The resolving power of the instrument was set to 0.7 Da (Full Width Half Maximum) for the first and third quadrupole. Data were acquired using a Chrom Filter peak width of 4.0 sec.
Data processing:
Peak areas and area ratios were calculated within Skyline (33) . All individual selected reaction monitoring transitions and integration areas were manually inspected and re-integrated as needed by trained experimenters.
Statistics: Reproducibility of Peptide Quantification and Calculation of Protein Level Measures: See
Supplement.
Proteins enriched in synaptosomes: Of the 348 proteins quantified in the synaptosome fractions, 159 had synaptosome levels that were significantly enriched over their homogenate levels as defined by a Bonferroni corrected p < 0.05 and a synaptosome/homogenate fold change > 1.25 (Table S4) . Statistical analysis of Szcontrol synaptosome differences were limited to these proteins.
Effects of PMI: See Supplement
Differential Expression Analysis: Limma-Voom(34) was performed to detect the difference between Sz and control samples in homogenate and synaptosome proteins, respectively. Both unadjusted and adjusted pvalues were obtained (Tables S2 and S3 ). For additional detail see Supplement.
Network Analysis: Weighted Gene Co-expression Network Analysis (WGCNA)(35) was used to investigate the pattern of co-regulated protein expression. See Supplement for details.
Comparison to PsychENCODE transcriptome findings: See Supplement.
Tables S2 and S3 report the module memberships for homogenate and synaptosome proteins, respectively. Tables S9 and S10 report the Eigenprotein values for each subject from the homogenate and synaptosome modules. Tables S11 and S12 report the full list of enriched terms for the homogenate and synaptosome modules, respectively.
Results:
Synaptosome protein yield is lower in Sz A1. Total synaptosome yield (ug protein / mg grey matter) was 33% lower (paired t-test, -0.21, 95% CI: -0.31 to -0.1, p = 4E -4 ) in Sz subjects (Figure 2A ). Haloperidol-treated monkeys had ~30% greater synaptosome yield relative to vehicle (unpaired t-test, 0.25±0.8, 95% CI: 0.047 to 0.44, p = 0.02, Figure 2B ). PMI was associated with decreased synaptosome yield in the mouse PMI model (r = -0.84, CI = -0.98 to -0.1, p = 0.035, Figure 2C ), but not in the human cohort ( Figure S1A ). pH correlated with synaptosome yield in the human cohort (r = 0.37, CI = 0.1746 to 0.5418, p = 4E -4 , Figure S1B) ; however, yield was still significantly decreased in Sz (linear regression, p = 0.011) while controlling for pH. To control for the lower synaptosome yield in Sz, the same amount of total synaptosome protein from all subjects and animals was used for MS analyses. , Table S13 ). Figure 4E .
depicts the number of proteins in the Turquoise module that contribute to the selected gene ontologies, and the proportion of those that were altered in Sz, in a chord diagram.
The synaptosome proteome organized into three highly distinct modules (Figure 4B & D , Table S13 ). Figure 4F . depicts the numbers of proteins in the Blue module that contribute to the selected gene ontologies, as well as the proportion of those that were altered in Sz. In line with the analysis above, the 38 proteins whose synaptosome alterations were not Similarities with reported transcriptome alterations. We did not observe a significant overlap between mRNA and homogenate protein alterations or mRNA and synaptosome protein alterations (Figure S14A & B) .
There was, however, a small but significant (r = 0.15, CI = 0.05048 to 0.2423, p = 3E -3 ) correlation between mRNA and homogenate protein Sz-control fold-changes ( Figure S14C ). No correlation was observed between mRNA and synaptosome protein Sz-control fold changes.
Discussion:
We observed robust differences in A1 homogenate and synaptosome protein levels in Sz. These differences organized into distinct co-regulation network alterations. Synaptosome levels of Mitochondrion and Postsynaptic Membrane proteins were generally lower in Sz, highly co-regulated, and did not appear to be driven by lower protein levels in the total homogenate. Homogenate levels of Nuclear and Mitochondrion proteins were lower in Sz, but were not correlated with synaptosome Mitochondrion and Postsynaptic
Membrane proteins in disease. Each of these findings is discussed in turn below.
Synaptosome Mitochondrion and Postsynaptic Membrane Proteins:
Synaptosome alterations in the Mitochondrion and Postsynaptic Membrane module included a diverse array of proteins that were highly co-regulated, were mostly (but not uniformly) decreased in Sz, and are believed to localize to different synaptic microdomains. Specifically, this module included mitochondrial proteins (e.g. ADT3 and ATPA); ionotropic glutamate receptor subunits (NMDZ1, GRIA2, and GRIA3); GABA receptor subunits (GBRA1, GBRB1, and GBRG2); ion transporters (S12A5); adaptor proteins (ANK1 and known about Sz cytoarchitectonics, our findings suggest a robust, broad, and highly coordinated rearrangement of the synaptic proteome impacting both glutamate and GABA synapses as well as presynaptic bioenergetics. However, it is possible that a subset of our findings are driven by the loss of specific cellular or synaptic compartments in concert with altered protein levels in others. This question will ultimately have to be addressed by multiple-label confocal microscopy, RNA-scope, or electron microscopy studies, guided by our findings.
The majority of these synaptosome alterations were not explained by underlying changes in total homogenate protein levels, further suggesting that they are driven by alterations in local mitochondrial trafficking or synaptic proteostasis. Indeed, decreased mitochondrial number at axon terminals have been observed in Sz (40) and cellular mechanisms that regulate synaptic proteostasis are essential for synapse formation and plasticity and have previously been implicated in Sz. For example, the ubiquitin-proteasome system, a key regulator of synaptic protein stability, is essential for LTP and learning (41, 42) and has been implicated in Sz pathology by unbiased genetic analyses (43, 44) . Thus, it is not surprising that ubiquitinproteasome system alterations have been directly observed in Sz patient tissue (45) (46) (47) . Similarly, phosphorylation is a well-documented regulator of glutamate receptor trafficking (48) and altered kinase activity has recently been observed in Sz (49, 50) . In addition to posttranslational modification, alternative isoform expression and non-synonymous mutations can produce proteins with drastically different synaptic trafficking or anchoring properties (51, 52) and have also been recently implicated in Sz (53) . In line with the results of these previous studies, our findings support a role for altered mitochondrial trafficking and synaptic proteostasis in Sz.
As neuronal excitation, inhibition, and bioenergetics are tightly balanced, it is not surprising that synaptic levels of these proteins are highly co-regulated. Considering the large body of work implicating postsynaptic glutamate receptor signaling in both Sz etiology and synaptic plasticity, it is a reasonable hypothesis that proteostatic alterations at excitatory postsynaptic compartments are the primary insult. For example, synaptosome levels of GRIA2, GRIA3, and S12A5 were decreased in Sz. Trafficking of GRIA2/3 containing AMPA receptors to new spines is essential for their potentiation and stabilization (54), as is synaptic S12A5 (55) (56) (57) . Subsequent decreases in synaptic mitochondrial and GABA receptors would then reflect homeostatic plasticity downstream of this decreased excitatory drive. Alternatively, presynaptic mitochondria are essential for bouton development(58) and activity (59) . Thus, altered mitochondrial transport to the presynaptic compartment could also contribute to synaptic pathology in Sz.
Cellular Homogenate Mitochondrion Proteins:
We found reduced Mitochondrion protein levels in Sz cellular homogenates, consistent with numerous reports of lower tissue-wide expression of mitochondrial transcripts (44, (60) (61) (62) , proteins (63) , and enzymatic activity (64, 65) in the cortex of Sz subjects. As alterations in cell numbers have not been observed in Sz A1, these alterations likely reflect differences in cellular protein levels. Interestingly, cellular homogenate Nuclear
and Mitochondrion Eigenprotein values and synaptosome Mitochondrion and Postsynaptic Membrane
Eigenprotein values were highly correlated in controls, but not in Sz (Figure S13 ), indicating that cellular and synaptic mitochondria regulation are uncoupled in disease. This finding is consistent with the highly dynamic and responsive nature of the mitochondrial organelle; mitochondria localized to synaptic compartments would be specifically reactive to an altered synaptic micro-environment compared to mitochondria in other cellular domains.
Relationship to transcriptome alterations:
The homogenate protein alterations were weakly, but significantly, correlated with previously observed mRNA alterations in Sz(53), which is in line with multiple reports that mRNA and protein levels are only modestly correlated (66) (67) (68) . Multiple processes beyond transcription regulate synaptic protein levels, such as RNA trafficking, translation, and protein trafficking. Thus, it is not surprising that synaptic protein alterations were not associated with previously reported mRNA alterations in
Sz. This absence of a link between the synaptic proteome and the transcriptome (and, by extension, the genome) highlights a critical gap in our current understanding of Sz etiology and the need to investigate additional molecular features that regulate the synaptic proteome in patient tissue.
Conclusion:
We identified robust evidence of synaptic proteome alterations in the A1 of Sz. Some of these alterations appeared to be driven by tissue-wide changes, while others were exclusive to the synaptic compartment. Our findings are in-line with previous reports of postsynaptic glutamate receptor and mitochondrial impairments in Sz; identifying synapse specific alterations as well as providing for a link between the two. These findings provide a map to guide future studies into the upstream drivers of these synaptic impairments as well as their effects on specific cortical cells and circuits. Future proteomic studies will be required to determine how altered ubiquitination, phosphorylation, and isoform expression may each contribute to synaptic proteostasis impairments in Sz, while microscopy studies will be required to identify the cortical cell types and circuits to which these postsynaptic and mitochondrial alterations localize. Table S1 ). Paired subject samples were processed together throughout all experiment steps (e.g. S1 & C1, S2 & C2). A randomized block design was utilized with different sample orders for tissue collection, synaptosome enrichment, standard addition, trypsin digestion, and targeted MS. Methodological controls were included to monitor variably in synaptosome enrichment; standard addition and trypsin digestion; and targeted MS. All experimenters were blinded during sample preparation, MS analysis, and peak integration. A. Grey matter was collected from Heschl's Gyrus in 40 μm sections and frozen at -80°C. B. The ultra-centrifuge rotor used for synaptosome enrichment has limited capacity at 6 tubes. To monitor reproducibility across synaptosome enrichment 1g of superior temporal gyrus grey matter from a low PMI control was pulverized in liquid nitrogen and divided into 50 mg aliquots. C. Two aliquots of these Enrichment Controls (EC) were included in every third rotor run. D. The resulting homogenate and synaptosome fractions were then reordered into separate blocks and processed independently for the remainder of the protocol. Micro-BCA was used to determine total protein amounts. A pooled control (PC) was then created from all samples within each fraction (homogenate or synaptosome) and divided into 8 aliquots to monitor variability in addition of [ 13 C6]brain ISTD and trypsin digestion. E. The samples were again reordered and digested with trypsin. F. The samples were reordered a final time, and a single mass spectrometry control (MC) to monitor instrument stability was created by mixing a homogenate PC and a synaptosome PC. G. All samples were analyzed in duplicate, with the sample order run first forwards and then backwards. ECs were distributed randomly throughout the run order, while PCs and the MC were analyzed every 10-12 injections. H. Integration of all light/heavy peak pairs were manually checked, and re-integrated if needed, by trained personnel blinded to sample. I. Superior temporal gyrus grey matter from male monkeys treated chronically with haloperidol, clozapine, or vehicle (n = 6/group) was used to monitor antipsychotic drug effects. J. Cortical hemispheres from mice with modeled PMIs from 0 -30 hours were used to monitor the effects of PMI on homogenate and synaptosome protein levels. Monkey grey matter and mouse cortices were processed and analyzed contemporaneously and using an identical protocol and [ 13 C6]brain ISTD preparation as described above, with the omission of the ECs. Total µg of protein in each synaptosome preparation was measured by micro-BCA. This value was then normalized to wet tissue weight to calculate synaptosome yield (µg total synaptosome protein / mg tissue). Synaptosome yield was decreased in Sz (A.) and increased in superior temporal gyrus tissue from monkeys treated with haloperidol, but not olanzapine (B.). Synaptosome yield was decreased in a linear fashion with PMI in the mouse cortical tissue (C.). Group n is provided in each bar. Heat maps report the fold-change (Sz/control) for the 63 significantly altered synaptosome proteins in the synaptosome fraction (Syn), as well as the fold-change of those proteins in the homogenate fraction (Hom). Additionally, to assess the relationship between protein homogenate levels and synaptosome levels, we calculated synaptosome enrichment values (the ratio of a protein's synaptosome levels over its homogenate levels) for each subject. Syn/Hom columns report the fold-change (Sz/control) for this metric. C. Lists the proteins for which the synaptosome enrichment values do not differ significantly between Sz and control; the synaptosome protein level differences in Sz are normalized by the homogenate level differences, suggesting that these synaptosome protein differences are driven by alterations in cell-wide protein expression (or degradation). D. Lists the proteins for which the synaptosome enrichment values differ between Sz and control significantly in the same direction as the synaptosome levels changes; the synaptosome level differences in Sz are not normalized by homogenate level changes, suggesting that mechanisms other than cell-wide protein expression (or degradation) are driving these effects. Darker shading denotes proteins that were significantly altered in Sz. Node sizes are proportional to each proteins' degree of connectivity. Line weights represent the strength of between-protein correlations.
Funding:
Only proteins with a weighted node connectivity > 0.15 were visualized. To investigate module biology, each module was first characterized by function/compartment using functional gene annotation analysis (e.g. Turquoise: Nuclear and Mitochondrion). Second, modules were tested for enrichment of Sz altered proteins, identifying the homogenate Nuclear and Mitochondrion module (Turquoise p = 6.2E -6 ) as well as the synaptosome Mitochondrion & Postsynaptic Membrane (PSM) (Blue p = 1.5E -5 ). Finally, we tested the difference in module Eigenprotein values between Sz and controls, identifying the Turquoise (7E -5 ), Blue (2.7E -5 ), and Red (0.015) modules as altered in Sz. ▲ = modules significantly enriched for proteins that differed significantly between Sz and control. ◙ = modules whose Eigenprotein values differed significantly between Sz and control. The chord figures depict the number of proteins in the Turquoise (E.), Blue (F.), and Red (G.) modules that contribute to the selected gene ontologies. Proteins contributing to ontologies are depicted as rectangles, with darker colors denoting those significantly altered in Sz. Proteins not contributing to the ontologies are depicted as lines, again with darker colors denoting significant alterations in Sz.
